Association of Plasma Ceramides and Sphingomyelin With VLDL apoB-100 Fractional Catabolic Rate Before and After Rosuvastatin Treatment

作者：Ng Theodore W K; Ooi Esther M M; Watts Gerald F; Chan Dick C; Meikle Peter J; Barrett P Hugh R^*

来源：Journal of Clinical Endocrinology & Metabolism, 2015, 100(6): 2497-2501.

DOI：10.1210/jc.2014-4348

Introduction: The objective of the study was to examine post hoc associations between plasma sphingolipids and lipoprotein kinetics in men with the metabolic syndrome after rosuvastatin treatment.
Materials and Methods: Plasma sphingolipid profiling, determined by tandem mass spectrometry, was performed in a randomized, double-blind, triple-crossover trial (n = 12) of 5-week treatment periods with placebo or rosuvastatin (10 or 40 mg/d) with 2-week washouts between treatments.
Results and Discussion: Baseline plasma ceramides were associated with very low-density lipoprotein (VLDL) apolipoprotein (apo)-B-100 concentration (r = 0.58, P <.05) andinversely with VLDL apoB-100 fractional catabolic rate (FCR; r = -0.67, P =.02). Posttreatment changes with rosuvastatin (40 mg/d) in plasma ceramideswereinversely associated with VLDL apoB-100FCR(r = -0.62, P =.03) independent of changes in plasma triglycerides, cholesterol, and low-density lipoproteincholesterol. By contrast, baseline and postrosuvastatin treatment plasma sphingomyelin levels were not associated with apoB-100 kinetics. Plasma ceramides and sphingomyelin were not associated with the kinetics or concentrations of high-density lipoprotein apoA-I, and low-density lipoprotein apoB. In the metabolic syndrome, the ability of rosuvastatin to increase VLDL apoB-100 FCR may reflect ceramide-specific mechanistic actions and/or sphingolipid exchange.

• 出版日期2015-6